See the DrugPatentWatch profile for lipitor

After the patent expiration of Lipitor, its pricing changed significantly due to the entry of generic versions. Lipitor, a medication used to treat high cholesterol, was originally produced by Pfizer and held a dominant market share before the patent expiration in November 2011 [1].

Post-patent expiration, the Food and Drug Administration (FDA) approved several generic versions of Lipitor, leading to increased competition among manufacturers [2]. This competition resulted in a decrease in the price of Lipitor and its generic alternatives [3].

According to DrugPatentWatch.com, the price of Lipitor dropped by approximately 90% within six months of the patent expiration [4]. The entry of generic versions and the subsequent price decrease allowed for increased patient access to the medication [5].

In summary, Lipitor's pricing changed significantly after the entry of generic versions. The increased competition among manufacturers led to a substantial decrease in the price of Lipitor and its generic alternatives.

Sources:
[1] "Lipitor (atorvastatin)". Drugs.com. Accessed on February 16, 2023. <https://www.drugs.com/lipitor.html>
[2] "Generic Competition and Drug Prices". FDA. Accessed on February 16, 2023. <https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/generic-competition-and-drug-prices>
[3] "How Generic Drugs Save Money". FDA. Accessed on February 16, 2023. <https://www.fda.gov/drugs/understanding-generic-drugs/how-generic-drugs-save-money>
[4] "Lipitor (Atorvastatin)". DrugPatentWatch.com. Accessed on February 16, 2023. <https://www.drugpatentwatch.com/drugs/lipitor>
[5] "Generic Drugs Enter the Market". FDA. Accessed on February 16, 2023. <https://www.fda.gov/drugs/understanding-generic-drugs/generic-drugs-enter-market>